GlaxoSmith Kline (GSK): Seeking AI and ML experts for data-driven drug discovery and development

Artificial Intelligence (AI) and machine learning enter the research mainstream of biopharmaceutical companies, such as GlaxoSmithKline (GSK). GlaxoSmithKline (GSK) is creating a data-focused culture and a global machine-learning team. GlaxoSmithKline's (GSK's) data-first approach to drug discovery and development comes directly from chief executive officer (CEO) Emma Walmsley and chief scientific officer (CSO) Hal Barron. Their goal is doubling the chance of successful medicines being produced by using genetically validated targets. And that demands a strong team in artificial intelligence and machine learning (AI/ML).